KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Operating Leases (2019 - 2025)

Nektar Therapeutics has reported Operating Leases over the past 7 years, most recently at $65.3 million for Q4 2025.

  • Quarterly results put Operating Leases at $65.3 million for Q4 2025, down 21.09% from a year ago — trailing twelve months through Dec 2025 was $65.3 million (down 21.09% YoY), and the annual figure for FY2025 was $65.3 million, down 21.09%.
  • Operating Leases for Q4 2025 was $65.3 million at Nektar Therapeutics, down from $69.7 million in the prior quarter.
  • Over the last five years, Operating Leases for NKTR hit a ceiling of $134.6 million in Q1 2021 and a floor of $65.3 million in Q4 2025.
  • Median Operating Leases over the past 5 years was $104.0 million (2023), compared with a mean of $102.5 million.
  • Biggest five-year swings in Operating Leases: dropped 5.44% in 2021 and later dropped 21.09% in 2025.
  • Nektar Therapeutics' Operating Leases stood at $125.7 million in 2021, then fell by 10.27% to $112.8 million in 2022, then dropped by 12.68% to $98.5 million in 2023, then decreased by 16.06% to $82.7 million in 2024, then fell by 21.09% to $65.3 million in 2025.
  • The last three reported values for Operating Leases were $65.3 million (Q4 2025), $69.7 million (Q3 2025), and $74.1 million (Q2 2025) per Business Quant data.